Erectile dysfunction management for the future

Journal of Andrology

Volumn 30, Issue 4, 2009, Pages 391-396

  Burnett, Arthur L ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Erection; Gene therapy; Growth factor therapy; Penis; Pharmacotherapy; Regenerative medicine

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

CONFERENCE PAPER; ERECTILE DYSFUNCTION; GENE THERAPY; HUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SEXUAL DYSFUNCTION; SEXUAL INTERCOURSE;

ERECTILE DYSFUNCTION; GENE THERAPY; HUMANS; MALE; PENILE ERECTION; PENIS; PHOSPHODIESTERASE INHIBITORS; REGENERATIVE MEDICINE;

EID: 68549085294     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.006106     Document Type: Conference Paper

References (27)

1. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417-450.
2. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. 2005;76:1-21. (Pubitemid 41033401)
3. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, Knapp WH, Hartmann U, Jonas U. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology. 2001;57:193-198. (Pubitemid 32065855)
4. Bella AJ, Lin G, Cagiannos I, Lue TF. Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury. Asian J Androl. 2008;10:54-59.
5. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002;14:8-14. (Pubitemid 34188625)
6. Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, de la Taille A, Shabsigh A, Frank J, Shabsigh R. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. Urology. 2005;66:665-670. (Pubitemid 41242357)
7. Burnett AL, Lue TF. Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic surgery. J Urol. 2006;176:882-887.
8. Burnett AL, Musicki B, Jin L, Bivalacqua TJ. Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets. 2006;10:445-457. (Pubitemid 43949958)
9. Cawello W, Schweer H, Dietrich B, Seyberth HW, Albrecht D, Fox A, Hohmuth H. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction. J Urol. 1997;158:1403-1407. (Pubitemid 27391207)
10. Christ GJ, Brink PR, Melman A, Spray DC. The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle. Int J Impot Res. 1993;5:77-96.
11. Christ GJ, Maayani S, Valcic M, Melman A. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness and age and disease in isolated tissues. Br J Pharmacol. 1990;101:375-381. (Pubitemid 20292893)
12. Christ GJ, Melman A. The application of gene therapy to the treatment of erectile dysfunction. Int J Impot Res. 1998;10:111-112. (Pubitemid 28286829)
13. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16(suppl 1):S4-S7. (Pubitemid 38993075)
14. Falke G, Yoo JJ, Kwon TG, Moreland R, Atala A. Formation of corporal tissue architecture in vivo using human cavernosal muscle and endothelial cells seeded on collagen matrices. Tissue Eng. 2003;9:871-879. (Pubitemid 37296819)
15. Giuliano FA, Rampin O, Benoit G, Jardin A. Neural control of penile erection. Urol Clin N Am. 1995;22:747-766.
16. Guidone G, Müller D, Vogt K, Mukhopadhyay AK. Characterization of VIP and PACAP receptors in cultured rat penis corpus cavernosum smooth muscle cells and their interaction with guanylate cyclase-B receptors. Regul Pept. 2002;108:63-72. (Pubitemid 35239861)
17. Holmquist F, Andersson KE, Favaeus M, Hedlund H. K(+)-channel openers for relaxation of isolated penile erectile tissue from rabbit. J Urol. 1990;144:146-151. (Pubitemid 20221303)
18. Jin L, Burnett AL. Rhol/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clin Sci (Lond). 2006;110:153-165. (Pubitemid 43241477)
19. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165-1176. (Pubitemid 44975134)
20. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol. 2001;91:1269-1273. (Pubitemid 32803922)
21. National Institutes of Health. Impotence. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 1992;10:1-33.
22. Podlasek CA, Meroz CL, Korolis H, Tang Y, McKenna KE, McVary KT. Sonic hedgehog, the penis and erectile dysfunction: a review of sonic hedgehog signaling in the penis. Curr Pharm Des. 2005;11:4011-4027. (Pubitemid 41672473)
23. Strong TD, Gebska MA, Burnett AL, Champion HC, Bivalacqua TJ. Endothelium-specific gene and stem cell-based therapy for erectile dysfunction. Asian J Androl. 2008;10:14-22.
24. Venkateswarlu K, Giraldi A, Zhao W, Wang HZ, Melman A, Spektor M, Christ GJ. Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium and channel openers. J Urol. 2002;168:355-361. (Pubitemid 34640856)
25. Wagner G. Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction. Int J Impot Res. 2001;13(suppl 3):S1-S2.
26. Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides. 2005;26:1972-1977.
27. Xie D, Annex BH, Donatucci CF. Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction. Asian J Androl. 2008;10:23-27.